The Association of Clinical Research Organizations (ACRO), which represents clinical outsourcing companies, reported late last fall that its members have expanded their payroll by 122% in the past 10 years and now account for over 72,000 jobs both in the United States and abroad. ACRO attributes this job growth to the 156% increase in revenues since 2001, or a compound annualized rate of 11%.
“The capability of ACRO members to provide the full spectrum of drug development services required to bring new medicines to market has led to tremendous growth in the industry over the past 10 years,” said Joe Herring, ACRO Immediate Past Chair, and Chairman and CEO of Covance. “The biopharmaceutical industry has recognized our efficiency, quality and commitment to research ethics, and ACRO members now constitute a large—and growing— share of the global drug development infrastructure.”
Among other survey findings, ACRO members:
According to ACRO’s Executive Director, Doug Peddicord, PhD, the jobs that CROs have created over the past 10 years is due to their tremendous growth. “Our members continue to expand the range and scope of their services, from drug discovery through post-approval studies, developing deep expertise in complex areas like vaccines, biosimilars, comparative effectiveness research, and regenerative medicine.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.